![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H18BrN3O3 |
Molar mass | 368.231 g·mol−1 |
3D model (JSmol) | |
| |
|
MDMB-5Br-INACA is an indazole-3-carboxamide derivative which has been sold as a designer drug. [2] Surprisingly it has been reported to produce psychoactive activity despite the lack of a "tail" group at the indazole 1-position, but is likely of relatively low potency as a CB1 agonist and has been encountered being misrepresented as other illicit drugs such as MDMA. [3] [4] This reported psychoactive activity has been limitedly reported on but could be related to activity beyond the cannabinoid receptors due to vague structural relation to compounds like 1Z2MAP1O.
MDMB-5Br-INACA is believed to be used as a precursor in the synthesis of synthetic cannabinoids. It has been sold online as a "chemistry kit" with other compounds required to complete the reaction. This reaction would complete MDMB-5Br-INACA by giving it a "tail" group required for high cannabinoid activity. Other precursors lacking a tail chain have also been marketed such as (ADB-5-Br-INACA), [5] (CH-IATA), (ADB-IACA), and (ADB-5’Br-EZO-CA). This may be due to increasing legality changes worldwide on synthetic cannabinoids. [6] [7]
In the United States, MDMB-5Br-INACA is unscheduled at the federal level as of May 22nd, 2023.
North Dakota has placed MDMB-5Br-INACA (along with ADB-5'Br-BINACA, ADB-5'Br-BUTINACA and ADB-5-Br-INACA) into Schedule I on 04/27/2023. [8]